Aim ImmunoTech plans combo study of Ampligen and FluMist for avian flu

AIM ImmunoTech Inc.

Plans to file IND for trial combining Ampligen with AstraZeneca's FluMist to target avian influenza.
Prior UAB clinical data showed Ampligen + FluMist induced cross-reactive antibodies against H5N1, H7N9, H7N3.
Pre-clinical work demonstrated 50-100% survival in mice challenged with H5N1 variants vs. 0-60% naive controls.
AIM has engaged CRO Amarex for IND application and study management; seeking government/industry grants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.